ProCE Banner Activity

ReFocus Phase I/II Trial of RLY-4008 in Patients With FGFR Inhibitor–Naive Cholangiocarcinoma With FGFR2 Alteration

Slideset Download
Conference Coverage
RLY-4008, a selective FGFR2 inhibitor, showed promising efficacy and safety in patients with FGFR inhibitor–naive cholangiocarcinoma with FGFR2 fusion or rearrangement in the phase I/II ReFocus trial.

Released: September 22, 2022

Expiration: September 21, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp